pyrotinib: Clinical Trials

16 trials of pyrotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 unknown, 4 completed, 4 recruiting, 1 not yet recruiting. 16 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Unknown 7, Completed 4, Recruiting 4, Not yet recruiting 1
Phase 29Unknown 5, Recruiting 3, Not yet recruiting 1

Follow pyrotinib: new trials by email Literature Review of pyrotinib trials Research Report on pyrotinib

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer
Phase 1 / Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital942025-06-232026-07-16
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
SHR-A1811, Bevacizumab, Pyrotinib - Breast Cancer Metastatic, Breast Cancer Brain Metastases
Phase 1 / Phase 2RecruitingFudan University742025-01-082025-02-06
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
Pyrotinib low dose group, Pyrotinib normal dose group - Breast Cancer
Phase 1RecruitingThe First Affiliated Hospital with Nanjing Medical University2002024-11-012025-01-13
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies - HER2-expressing Advanced Solid Tumors
Phase 1 / Phase 2RecruitingJiangsu HengRui Medicine Co., Ltd.3642023-08-112024-08-05
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
pyrotinib tablet, Montmorillonite Power, Loperamide - HER2-positive Recurrent / Metastatic Breast Cancer
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.362022-03-082022-12-23
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Docetaxel, trastuzumab, Pyrotinib - Metastatic Breast Cancer
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.972020-05-282023-09-18
A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
Pyrotinib in combination with capecitabine - HER-2 Positive Colorectal Cancer
Phase 1 / Phase 2UnknownQingdao Zhixin Health Technology Co., Ltd.342020-01-102020-01-14
Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases
Pyrotinib Plus Capecitabine combined with brain radiotherapy - Breast Cancer, Brain Metastases
Phase 1 / Phase 2UnknownFudan University392020-01-022023-01-18
Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
pyrotinib tablet, Itraconazole capsule - Healthy Subjects
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.182019-09-182020-07-21
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
Dalpiciclib, Pyrotinib, Letrozole - Breast Cancer
Phase 1 / Phase 2UnknownFudan University592019-05-122023-03-07
FUSCC Refractory TNBC Umbrella (FUTURE)
Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel - Triple-negative Breast Cancer
Phase 1 / Phase 2UnknownFudan University1402018-10-182022-08-10
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Pyrotinib - Breast Cancer, Gastric Cancer
Phase 1UnknownHengrui Therapeutics, Inc.502015-06-012021-02-01
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
pyrotinib, Lapatinib, capecitabine - HER2 Positive Metastatic Breast Cancer
Phase 1 / Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.1282015-05-012018-07-09
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
Pyrotinib/Pyrotinib with Docetaxel - HER2 Positive Gastric Cancer
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.282014-09-012015-03-04
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
Pyrotinib - Breast Cancer
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.402013-01-012018-07-09

Conditions studied

Breast Neoplasms (8)  ·  Brain Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Stomach Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (7)  ·  Fudan University (4)  ·  Hengrui Therapeutics, Inc. (1)  ·  Qingdao Zhixin Health Technology Co., Ltd. (1)  ·  RemeGen Co., Ltd. (1)  ·  The First Affiliated Hospital with Nanjing Medical University (1)  ·  Tianjin Medical University Cancer Institute and Hospital (1)

Countries

China (15)  ·  United States (1)

Top investigators

Biyun Wang, Chief physician (1)  ·  Hongxia Wang, Chief physician (1)  ·  Junsheng Wang, MD (1)  ·  Xiaoli Yu, MD PhD (1)  ·  Yongmei Yin, Ph.D (1)  ·  Zhimin U Shao, Professor (1)

Results publications

PMID 39024777, PMID 27602761, PMID 32719455, PMID 32898333, PMID 35105939, PMID 35321427, PMID 36135045, PMID 36803645, PMID 37081722, PMID 38175627, PMID 38290515, PMID 40433999, PMID 40743286